||Myricetin is a naturally-occurring flavonoid found in many grapes, berries, fruits, vegetables, herbs, as well as other plants. Walnuts are a rich dietary source. It has been shown
||Isoproterenol is a potent beta-adrenergic agonist with the peripheral vasodilator, bronchodilator, and cardiac stimulating properties.
||CAL-130 is a PI3Kδ and PI3Kγ inhibitor (IC50s: 1.3 and 6.1 nM).
||CAL-130 Hydrochloride is a PI3Kδ and PI3Kγ inhibitor (IC50s: 1.3 and 6.1 nM).
||CAL-130 Racemate is the racemate of CAL-130. CAL-130 is a PI3Kδ and PI3Kγ inhibitor (IC50s: 1.3 and 6.1 nM).
||CHMFL-PI3KD-317 is a highly potent, selective, and orally active PI3Kδ inhibitor (IC50: 6 nM) with the antiproliferative effects on cancer cells. It inhibits PI3Kδ-mediated Akt T
||Duvelisib R enantiomer
||Duvelisib R enantiomer is an enantiomer with low activity of Duvelisib and is an inhibitor of PI3K.
|| Pictilisib dimethanesulfonate is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).
||Idelalisib is a highly selective and orally bioavailable p110δ inhibitor. Idelalisib D5 is a deuterium labeled Idelalisib.
||LAS191954 is a selective, potent and orally active PI3Kδ inhibitor for inflammatory diseases treatment(IC50 : 2.6 nM).
||MSC2360844 is a potent, orally active and selective inhibitor of PI3Kδ(IC50 of 145 nM).
||NVP-QAV-572 is a inhibitor of PI3K(IC50 of 10 nM).
||ON 146040 is a potent inhibitor of PI3Kα and PI3Kδ (IC50≈14 and 20 nM, respectively) .
||PARP/PI3K-IN-1 is a potent inhibitor of PARP/PI3K(pIC50 values of 8.22).
||Parsaclisib is a potent and selective inhibitor of PI3Kδ(IC50 of 1 nM at 1 mM ATP)
||PI3K/HDAC-IN-1 is a potent PI3K and HDAC dual inhibitor(IC50s of 8.1 nM and 1.4 nM, respectively).
||PI3K-IN-10 is a potent inhibitor of pan-PI3K .
||PI3K-IN-6 is an oral active and highly selective inhibitor of phosphoinositide 3-kinase (PI3K) β/δ(IC50 values of 7.8 nM/5.3 nM , respectively).
||PI3K-IN-9 is a potent and selective inhibitor of PI3Kδ(IC50 of 8.9 nM).
||PI3K/mTOR Inhibitor-2 is a potent dual inhibitor of pan-PI3K/mTOR(PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ/mTOR with IC50s of 3.4/34/16/1/4.7 nM).
||PI3K/mTOR Inhibitor-1 is a potent, orally bioavailable dual inhibitor of PI3K/mTOR (PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ/mTOR with IC50s of 20/376/204/46/186 nM)
||PI3Kdelta inhibitor 1
||PI3Kdelta inhibitor 1 is a potent, selective and orally available inhibitor of PI3Kδ with an IC50 of 1.3 nM.
||PI3Kδ-IN-1 is an efficacious PI3Kδ inhibitor (IC50 of 1.7 nM).
||PI3kδ inhibitor 1
||PI3kδ inhibitor 1 is a selective inhibitor of PI3Kδ (IC50 of 3.8 nM).
||PI3Kγ inhibitor 1
||PI3Kγ inhibitor 1 is a inhibitor of PI3Kδ and PI3Kγ.
||PI3Kγ inhibitor 2
||PI3Kγ inhibitor 2 is an orally bioavailable inhibitor of PI3Kγ(Ki of 4 nM).
||AZD3458 is a potent and remarkably selective inhibitor of PI3Kγ (PI3Kγ, PI3Kα, PI3Kβ, and PI3Kδ with pIC50s of 9.1, 5.1, <4.5, and 6.5 , respectively).
||PI4KIII beta inhibitor 3
||PI4KIII beta inhibitor 3 is a novel and high effective inhibitor of PI4KIIIβ (IC50 of 5.7 nM).
||PI4KIIIbeta-IN-10 is a potent inhibitor of PI4KIIIβ (IC50 of 3.6 nM).
||PI4KIIIbeta-IN-9 is a potent inhibitor of PI4KIIIβ(IC50 of 7 nM). .
||PI3Kα/mTOR-IN-1 is a potent dual inhibitor PI3Kα/mTOR(an IC50 of 7 nM for PI3Kα in a cell assay, and Kis of 10.6 nM and 12.5 nM for mTOR and PI3Kα in a cell free assay , respec
||SAR405 suppresses autophagy induced either by starvation or by mTOR inhibition. SAR405 is a first-in-class and ATP-competitive inhibitor of PI3K class III isoform Vps34 (IC50=1.2
||Tenalisib (RP6530) is a potent and selective inhibitor of PI3Kδ and PI3Kγ(IC50 values of 25 and 33 nM, respectively.)
||Umbralisib R-enantiomer (TGR-1202 R-enantiomer) is an inhibitor of PI3Kδ, which is the less active enantiomer of TGR-1202.
||Vps34-IN-2 is a potent and selective Vps34 inhibitor(IC50s of 2 and 82 nM on the Vps34 enzymatic assay and the GFP-FYVE cellular assay, respectively).
||ZD-0892 is a selective and poten neutrophil elastaset inhibitor(human neutrophil elastase and porcine pancreatic elastase with Kis of 6.7 and 200 nM, respectively).
||(Z)-GW 5074 interacts with both mHTT (mutant huntingtin protein) and LC3.
||AMG 511 is a potent and orally available pan inhibitor of class I PI3Ks, with Kis of 4 nM, 6 nM, 2 nM and 1 nM for PI3Kα, β, δ and γ, respectively. AMG 511 exhibits anti-tumor
||BAY1082439 is a selective and orally bioavailable inhibitor of PI3Kα/β/δ, and also inhibits mutated forms of PIK3CA, with highly effective in inhibiting Pten-null prostate cance
||Dactolisib Tosylate (BEZ235 Tosylate) is an inhibitor of dual PI3K and mTOR kinase(IC50 values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively). Dactolisib Tosylate also inh
||CGS 15943 is an orally bioavailable non-xanthine antagonist of Adenosine Receptor. In transfected CHO cells, its Ki for human A1, A2A, A2B, and A3 Adenosine Receptors are 3.5, 4.2
||Copanlisib dihydrochloride is an ATP-competitive pan-class I PI3K inhibitor (IC50s: 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ, and PI3Kγ) with antitumor activit
||GDC-0077 is an orally available and selective inhibitor of PI3Kα (IC50: 0.038 nM). GDC-0077 is more selective for mutant versus wild-type PI3Kα. It exerts its activity by bindi
||GS-9901 is a highly selective and orally active inhibitor of PI3Kδ (IC50: 1 nM). It also has the potential to treat rheumatoid arthritis.
||Nemiralisib is a potent and highly selective inhibitor of PI3Kδ (pKi: 9.9).
||IPI-3063 is an effective and selective inhibitor of PI3K p110δ (IC50: 2.5 ± 1.2 nM).
||LY117018 shows antiproliferative effects on breast cancer cell lines. LY117018 is a Raloxifene analog and is a selective estrogen receptor modulator.
||BF738735 is an inhibitor of phosphatidylinositol 4-kinase III beta (IC50: 5.7 nM).
||SAR-260301 is an orally available and selective inhibitor of PI3Kβ (IC50: 23 nM).
||Sonolisib is an irreversible and pan-isoform inhibitor of PI3K (IC50=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ)).
||Umbralisib hydrochloride is a novel PI3Kδ inhibitor (IC50 and EC50 of 22.2 nM and 24.3 nM, respectively). Umbralisib hydrochloride is also active against CK1ε (EC50: 6.0 μM).
||Voxtalisib (SAR245409, XL765)Analogue is a dual inhibitor of mTOR/PI3K, mostly for p110γ ,also inhibits DNA-PK and mTOR.
||Buparlisib is an orally bioavailable specific oral inhibitor of the pan-class I PI3K (IC50s: 52/166/116/nM for p110α, p110β, and p110δ).
||INK 128 is an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2) with potential antineoplastic activity.
||AZD8055 is an ATP-competitive mTOR inhibitor (IC50: 0.8 nM in MDA-MB-468 cells). It is ~1,000-fold selective for mTOR over all PI3K isoforms.
||GSK2126458 is a small-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic activity.
||3-Methyladenine (3-MA) is a selective PI3KV inhibitor, and the IC50s against ps34 and PI3Kγ were 25/60 μM in HeLa cells, respectively.
||Idelalisib is a small molecule inhibitor of the PI3K catalytic subunit p110δ (IC50: 2.5 nM). The selectivity for p110δ is 40- to 300-fold than p110α/β/γ.
||Apitolisib, an effective, class I PI3K inhibitor for PI3Kα（IC50=5 nM）, PI3Kβ（IC50=27 nM）, PI3Kδ（IC50=7 nM）, PI3Kγ （IC50=14 nM）, is used in trials study of solid
||Alpelisib is an orally bioavailable PI3Kα inhibitor (IC50: 5 nM in a cell-free assay) with potential antineoplastic activity and minimal effect on PI3Kβ/γ/δ.
||CZC24832 is a selective inhibitor of PI 3-kinase γ.
||AZD2014 is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity.
||Gedatolisib is a highly effective dual inhibitor targeting the PI3Kα/γ (IC50: 0.4/5.4 nM)and mTOR (IC50: 1.6 nM) in the PI3K/mTOR signaling pathway.
||Duvelisib is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunom
||Pictilisib (GDC-0941) is a potent pan inhibitor of class I catalytic subunits of PI3K (IC50s: 3/33/3/75 nM for p110α/β/δ/γ).
||Taselisib is an orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) alpha isoform (PIK3CA), with potential antineoplastic activity.
||LY294002 is an inhibitor of PI3K (IC50s: 0.5/0.57/0.97 μM for PI3Kα/δ/β in cell-free assays). It also blocks autophagosome formation.
||Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis.
||APY0201 is a effective, highly specific, ATP-competitive PIKfyve inhibitor (IC50: 5.2 nM). It can interrupt the conversion of phosphatidylinositol 3-phosphate (PtdIns3P) to PtdIns(
||GSK2636771, an effective, specific, orally bioavailable, PI3Kβ inhibitor, has been used in cancer, lymphoma, solid neoplasm, recurrent solid neoplasm, and advanced malignant neopl
||PI-3065 is a novel potent and selective PI3K p110δ inhibitor.
||ETP-46464 is an effective and specific ATR inhibitor (IC50: 25 nM).
||Quercetin, a natural flavonoid present in vegetables, fruit, and wine, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor.
||Dactolisib is an orally bioavailable inhibitor of PI3K and mTOR (IC50s: 4 nM/5 nM/7 nM/75 nM, and 20.7 nM for p110α/p110γ/p110δ/p110β and mTOR).
||AS-605240 is an effective and specific inhibitor of PI3Kγ (IC50/Ki: 87.8 nM).
||CNX-1351 is a potent and isoform-selective targeted covalent PI3Kα inhibitor.
||PI3K-IN-2 is an orally bioavailable pan inhibitor of PI3K and inhibitor of the mTOR, with potential antineoplastic activity. PI3K-IN-2 inhibits the PI3K kinase isoforms alpha, beta
||PIK-75 Hydrochloride is a p110α inhibitor with IC50 of 5.8 nM (200-fold more potently than p110β), isoform-specific mutants at Ser773, and also potently inhibits DNA-PK with IC
||PIK-294 is a excellently specific p110δ inhibitor(IC50=10 nM).
||HS-173 is an effective PI3Kα inhibitor (IC50: 0.8 nM).
||GSK1059615 has been used in trials studying the treatment of Lymphoma, Solid Tumours, Endometrial Cancer, Solid Tumor Cancer, and Metastatic Breast Cancer.
||Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treat
||XL147 analogue is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ.
||Torkinib (PP 242) is a selective and ATP-competitive mTOR inhibitor (IC50: 8 nM). It also inhibits mTORC1/2 (IC50s: 30/58 nM).
||A66 is a specific and effective p110α inhibitor(IC50=32 nM).
||NU7026 is an effective DNA-PK inhibitor (IC50: 0.23 μM, in cell-free assays), 60-fold selective for DNA-PK than PI3K and no inhibition against both ATM and ATR.
||PIK-90, a DNA-PK and PI3K inhibitor, suppresses p110α( IC50=11 nM), p110γ(IC50=18 nM) and DNA-PK(IC50=13 nM) .
||PIK-93 is the first potent, synthetic PI4K inhibitor with IC50 of 19 nM; inhibits PI3Kα with IC50 of 39 nM.
||CH5132799 has been used in trials studying the treatment of Solid Tumors.
||IC-87114 is a specific PI3Kδ inhibitor(IC50=0.5 μM).
||TGX-221, an effective, specific, and cell membrane permeable inhibitor of the PI3K p110β catalytic subunit, is utilized for cancer treatment.
||PIK-75, a DNA-PK and PI3K inhibitor, suppresses DNA-PK(IC50=2 nM), p110α(IC50=5.8 nM) and p110γ(IC50=76 nM).
||TG100-115 is a PI3Kγ/δ inhibitor (IC50: 83/235 nM), with fewer effects on PI3Kα/β.
||Acalisib (GS-9820) is a potent and selective inhibitor of PI3Kδ.
||KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor.
||4-Hydroxyisoleucine (HIL) from fenugreek (Trigonella foenum-graecum) seeds is a potential insulinotropic (anti-diabetic) and anti-obesity amino acid. HIL stimulates glucose-depende
||Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth.
||Bakkenolide A has antifeedant and growth inhibitory effects on neonate variegated cutworms, it inhibits leukemia by regulation of HDAC3 and PI3K/Akt-related signaling pathways.
||Karanjin is a potent Volume-regulated anion channels(VRACs) current inhibitor, the VRAC inhibition might be responsible for its anti-angiogenic effects. Karanjin possesses antioxid
||Jolkinolide B has potent anti-inflammatory, and antitumor activities, it is able to enhance apoptosis of human leukemic HL-60 and THP-1 cells, at least in part, through downregulat
||Ponicidin has anti-leukemia, immunoregulatory and anti-inflammatory functions, it also has anti-viral function especially in the upper respiratory tract infection. Ponicidin has an
||MLN1117 (INK1117) is a p110α/β/γ/δ inhibitor (IC50: 15/4.5/1.9/13.39μM).
||PIK-inhibitors is a pan PI3K inhibitors,an analog of PI-103.
||Cytochalasin D is an actin inhibitor, the removal of actin stress fibers is crucial for the chondrogenic differentiation. It may be an inhibitor of some fertilization processes suc
||PIK-293 is a PI3K inhibitor, for PI3Kδ( IC50=0.24 μM), and less potent for PI3Kα/β/ γ.
||CC-223 is an orally available mTOR inhibitor with potential antitumor activity. CC-223 inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and
||Momordin Ic might represent a potential anticancer activity, by inducing apoptosis through oxidative stress-regulated mitochondrial dysfunction involving the MAPK and PI3K-mediated
||CC-115 is a inhibitor of mTOR/DNA-PK (IC50= 21/ 13 nM).
||NIH-12848 is a putative inhibitor of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) with an IC50 of 1 μM.
||GNE-477 is a potent and efficacious dual PI3K/mTOR inhibitor.
||GDC-0084 (RG7666) is a PI3K inhibitor with potential antineoplastic activity. GDC-0084 specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, th
||GDC-0326 is a potent and selective inhibitor of α-Isoform of Phosphoinositide 3-Kinase (PI3Kalpha inhibitor).
||SF2523 is a highly selective and potent inhibitor.
||Desmethyl-VS-5584 is a dimethyl analog of VS-5584, which is a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer.
||Autophinib is a potent autophagy inhibitor with a novel chemotype with IC50 values of 90 and 40 nM for autophagy in starvation induced autophagy assay and rapamycin induced autopha
||BQR-695 is a phosphatidylinositol 4-kinase (PI4K) inhibitor with IC50s of 80 and 3.5 nM for human PI4KIIIβ and Plasmodium variant of PI4KIIIβ, respectively.
||MTX-211, an inhibitor of EGFR and PI3K, is used for the therapy of cancer and other diseases.
||LX2343 is a BACE1 enzyme inhibitor with an IC50 value of 11.43±0.36 μM. LX2343 acts as a non-ATP competitive PI3K inhibitor with an IC50 of 15.99±3.23 μM. LX2343 stimulates aut
||Shikonin is a natural red naphthoquinone pigment, has antimicrobial, anti-tumor, and anti-inflammatory effects; a purified shikonin preparation is widely used for the production of
||TGR-1202 is a PI3Kδ inhibitor.
||Leniolisib (CDZ173) is a potent and selective PI3Kδ inhibitor (IC50: 11 nM).
||IPI-549 is an inhibitor of PI3Kγ (IC50 = 16, 3,200, 3,500, and >8,400 nM for PI3Kγ, PI3Kα, PI3Kβ, and PI3Kδ, respectively)
||CYNARIN is a natural product. It shows antioxidant and choleretic properties and is a potential immunosuppressive agent.
||Selective PI3Kδ Inhibitor 1
||Selective PI3Kδ Inhibitor 1 is a PI3Kδ Inhibitor(IC50 = 0.9 nM).
||Loureirin A has an inhibitory effect on platelet activation, perhaps through an impairment of PI3K/Akt signaling.Loureirin A negatively affects agonist-induced platelet aggregation
||XL388 is a highly effective, specifc, ATP-competitive inhibitor of mTOR ( IC50: 9.9 nM), 1000-fold selectivity than the closely related PI3K kinases.
||Torin 1 is an effective inhibitor of mTORC1/2 with (IC50: 2 nM/10 nM); has 1000-fold selectivity for mTOR than PI3K.
||BGT226 (NVP-BGT226) is a class I PI3K/mTOR inhibitor for PI3Kα/β/γ (IC50: 4/63/38 nM) .
||AZD 6482 is a potent and selective p110β inhibitor with IC50 of 0.69 nM and a PI3Kβ inhibitor with IC50 of 10 nM.
||VS-5584 is a pan-PI3K/mTOR kinase inhibitor.
||YM201636 (IC50=33 nM), a specific PIKfyve inhibitor, is less effective to p110α and insensitive to Fabl, which is yeast orthologue.
||PI-103 is a potent, cell-permeable, ATP-competitive inhibitor of PI3K family members (IC50s: 2/3/3/15/30/23 nM for p110α/β/δ/γ, mTOR, and DNA-PK).
||PI3K Inhibitor ZSTK474 is an orally available, s-triazine derivative, ATP-competitive phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity.
||AS-252424 is a potent and selective inhibitor of PI3Kγ with IC50 of 33 nM; >10 fold selectivity for PI3Kγ versus PI3Kα.
||PF-04691502 is a potent and selective inhibitor of PI3K and mTOR kinases with antitumor activity.
||Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-P
||OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, and more than 100-fold selectivity observed for mTOR than PI3Kα, PI3Kβ, PI3Kγ
||Copanlisib is a phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may resul
||PI3Kδ-IN-2 is a potent and selective inhibitor of PI3Kδ
||AS-604850 is a specific and ATP-competitive PI3Kγ inhibitor (IC50: 250 nM), 18-fold more selective for PI3Kγ than PI3Kα, and over 80-fold selectivity for PI3Kγ than PI3Kδ/β.
||CAY10505, a form of dehydroxyl of AS-252424, is a PI3Kγ inhibitor (IC50: 33 nM).
||GDC-0349 is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM, 790-fold inhibitory effect against PI3Kα and other 266 kinases. Phase 1.
||KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 of 8.6 nM and 4 nM, 0.5 nM, 0.1 nM respectively, less inhibition of PI3Kγ with IC50 of 0.59 μM.
||TG100713 is a pan-PI3K inhibitor against PI3Kγ, PI3Kδ, PI3Kα and PI3Kβ with IC50 of 50 nM, 24 nM, 165 nM and 215 nM, respectively.
||WYE-354(IC50=5 nM) is an effective, selective and ATP-competitive mTOR inhibitor. It blocks mTORC2/P-AKT(S473) and mTORC1/P-S6K(T389), not P-AKT(T308). The selectivity for mTOR is
||WYE-687 is an ATP-competitive and selective inhibitor of mTOR with IC50 of 7 nM; blocks mTORC1/pS6K(T389) and mTORC2/P-AKT(S473) but no effect observed on P-AKT(T308). Selectivity
||AMG319 is a potent and selective PI3Kδ inhibitor with IC50 of 18 nM, >47-fold selectivity over other PI3Ks. Phase 2.
||AZD8186 is an effective and specific PI3Kβ/δ inhibitor (IC50: 4/12 nM).
||AZD8835 is a mixed inhibitor of PI3Kα/δ (IC50: 6.2/5.7 nM), also with selectivity against PI3Kβ/γ (IC50: 431/90 nM).
||IITZ-01 is potent autophagy inhibitor with single-agent anticancer activity ( IC50 of 2.62 μM for PI3Kγ.)
||Deguelin is a PI3K/AKT Inhibitor, which is a natural product isolated from plants in the Mundulea sericea family.
||GNE-317, a PI3K/mTOR inhibitor, can pass through the blood-brain barrier (BBB).
||LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, DNA-PK, and mTOR. LY3023414 has been used in trials studying the treatment of Neoplasm, Solid Tumor, CO
||PF-4989216 is a potent and selective PI3K inhibitor with IC50 of 2 nM, 142 nM, 65 nM, 1 nM, and 110 nM for p110α, p110β, p110γ, p110δ, and VPS34, respectively.
||PIK-III, a selective inhibitor of VPS34 enzymatic activity, inhibits autophagy and results in the stabilization of autophagy substrates.
||Voxtalisib (SAR245409, XL765) is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.
||Vps34-IN1 is a potent and highly selective Vps34 inhibitor with IC50 of 25 nM invitro,which does not significantly inhibit the isoforms of class I as well as class II PI3Ks.
||GNE-493 is potent, selective, and orally available PI3K and mTOR inhibitor with potential anticancer activity.IC50s of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα, PI3Kβ, PI3
||PF-04979064 is a potent and selective PI3K and mTOR dual kinase inhibitor(Ki of 0.13 nM and 1.42 nM,respectively).
||TASP0415914 is an orally potent inhibitor of phosphoinositide 3-kinase γ (PI3Kγ). T
||VPS34 inhibitor 1 (Compound 19, PIK-III analogue)
||VPS34 inhibitor 1 (Compound 19, PIK-III analogue) is a potent and selective inhibitor of VPS34( IC50 : 15 nM)
||Dehydroglyasperin D exhibits anticancer, anti-inflammatory, anti-obesity, antioxidant and anti-aldose reductase effects, it inhibits the proliferation of HT-29 human colorectal can
||Tomatidine shows antibiotic, and anti-inflammatory activities, it significantly suppresses the activity of ACAT and leads to reduction of atherogenesis. Tomatidine inhibits the inv
||Delta-tocotrienol is a potential angiogenic inhibitor, it (2.5-5 microM) can significantly suppress human colorectal adenocarcinoma cells (DLD-1-CM) -induced tube formation, migrat
||Sennidin A, has two hydroxyanthraquinone-like moieties, exerts inhibition on NS3 helicase with IC50 values of 0.8 μM.
||Sennidin B stimulates glucose incorporation in rat adipocytes.
||Polyporenic acid C
||Polyporenic acid C shows inhibitory activity against human collagenase.
||8-Prenylkaempferol is an effective agent for attenuating pro-inflammatory NO induction, it may be an anti-inflammatory agent for suppressing influenza A virus-induced RANTES produc
||Alismol has antihypertensive action, it decreases cardiac output, heart rate and left ventricular pressure, but it increases coronary flow, it has been used for the prevention of a
||Alpha-Solanine alters antioxidative enzyme activities and MDA and PCO concentrations and GST activity in fat body and midgut.
||Bufarenogin has inhibitory activity on human kidney Na(+)/K(+)-ATPase, it has cytotoxicity against HepG2 and MCF-7 human cancer cells.
||Butin has antioxidant activity, can protect cells against H2O2-induced apoptosis, oxidative DNA damage and oxidative mitochondrial dysfunction; it attenuates oxidative stress by ac
||Citreorosein is a cAMP phosphodiesterase inhibitor, it has anti-inflammatory effect, inhibits proinflammatory cytokines production through the inhibition of both MAPKs and AKT-medi
||(+)-Syringaresinol shows inhibitory activity of Helicobacter pylori motility with the IC50 value is 50 microg/ml.
||Gossypetin has anti-mutagenic, anti-atherosclerotic, antioxidant, as well as cytoprotective and antimicrobial effects, it inhibits bone resorption through down-regulating lysosomal
||Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway, it has anti-prostate cancer (PCA) activity that is mediated
||Kaempferol 3-neohesperidoside has insulin-like properties in terms of glucose lowering, it stimulates glucose uptake in the rat soleus muscle via the PI3K and PKC pathways and, at
||Orobol is an inhibitor of tyrosine-specific protein kinase and phosphatidylinositol turnover, it has sensitization effect, it can produce produced cisplatin (DDP) sensitivity in hu
||Sulfuretin is a potent anti-oxidant, has protective effect against t-BHP-induced oxidative damage in human liver-derived HepG2 cells is attributable to its ability to scavenge ROS
||Taurocholic acid feeding shows cytoprotective effects on the biliary tree after adrenergic denervation of the liver; taurocholic acid feeding prevents tumor necrosis factor-alpha-i
||Zeylenone has good antitumor efficacy, it inhibits proliferation and induces apoptosis in cervical carcinoma cells via PI3K/AKT/mTOR and MAPK/ERK pathways. Zeylenone shows inhibito
||7-(4-Hydroxyphenyl)-1-phenyl-4-hepten-3-one as a beneficial compound to ameliorate the deleterious effects of Aβ on dendrite integrity and cell survival, and may provide new insig
||Cimiside E has anti-inflammatory activity, it selectively inhibits TNF-α-induced expression of VCAM-1 at least by upregulation of PPAR-γ, and signals for ERK1/2, PI3K, and PKC ar
||Communic acid has antibacterial activity, including against mycobacterial. trans-Communic acid has potential to be utilized as anti-wrinkling agents and cosmetic ingredients, as th
||Cudraflavone B has anti-proliferative activity, mouse brain monoamine oxidase (MAO) inhibitory effects, apoptotic actions in human gastric carcinoma cells and mouse melanoma cells,
||Dalbergioidin exhibits tyrosinase inhibitory activity with an IC50 of 20 mM. It shows a melanin biosynthesis inhibition zone in the culture plate of Streptomyces bikiniensis that h
||Dehydroglyasperin C is a potent NAD(P)H:oxidoquinone reductase (NQO1) and phase 2 enzyme inducer. Dehydroglyasperin C possesses potent antioxidant, cancer chemopreventive, and neur
||ExcisaninA may be a potent inhibitor of AKT signaling pathway in tumor cells, it can inhibit invasion by suppressing MMP-2 and MMP-9 expression, it may be a potential anti-metastat
||Hirsutenone has potent antioxidant activity, it shows significant free radical scavenging activity and exhibits inhibition effect on the mitochondrial lipid peroxidation.Hirsutenon
||Isoangustone A has antitumor activity, it can induce G1 cycle arrest in DU145 human prostate and 4T1 murine mammary cancer cells, it inhibits cell proliferation by targeting PI3K,
||Niazimicin are NF-B and PI3K inhibitors, which shows antimicrobial, hypotensive and spasmolytic activities. Niazimicin has potent antitumor promoting activity in the two-stage carc
||Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis, it can strongly suppress tum
||Uncarinic acid E
||Uncarinic acid E has anti-cancer activity, it induces apoptosis in HepG2 cells via accumulation of p53, alters the Bax/Bcl-2 ratio, and activates caspases, resulting in cytochrome
||740 Y-P is a potent and cell-permeable activator of PI3K.
||UCB9608 is a selective and orally active PI4KIIIβ inhibitor (IC50: 11 nM), selective over PI3KC2 α, β, and γ lipid kinases.
||Seletalisib (UCB5857) is a potent and specific PI3Kδ inhibitor (IC50: 12 nM).
||ETP-46321 is an effective and orally bioavailable PI3Kα/PI3Kδ inhibitor (Ki: 2.3/14.2 nM).
||NVP-BAG956 is an ATP-competitive PI3K inhibitor (IC50s: 34/56/112/444 nM for PI3Kδ/PI3Kα/PI3Kγ/PI3Kβ).